结核分枝杆菌孤儿细胞色素P450 CYP135B1的特征：参与抗结核药物SQ109的代谢而非抗菌活性

IF 4 2区医学 Q2 CHEMISTRY, MEDICINAL

ACS Infectious Diseases Pub Date : 2025-04-02 DOI:10.1021/acsinfecdis.4c0089310.1021/acsinfecdis.4c00893

Elodie Sadowski, Nicolas Pietrancosta, Romain Veyron-Churlet, Jean-Luc Boucher, Cédric Pionneau, Gilles Clodic, Lucrèce Matheron, Olivier Poch, Claudine Mayer, Emmanuelle Sachon* and Alexandra Aubry*,

{"title":"结核分枝杆菌孤儿细胞色素P450 CYP135B1的特征：参与抗结核药物SQ109的代谢而非抗菌活性","authors":"Elodie Sadowski, Nicolas Pietrancosta, Romain Veyron-Churlet, Jean-Luc Boucher, Cédric Pionneau, Gilles Clodic, Lucrèce Matheron, Olivier Poch, Claudine Mayer, Emmanuelle Sachon* and Alexandra Aubry*, ","doi":"10.1021/acsinfecdis.4c0089310.1021/acsinfecdis.4c00893","DOIUrl":null,"url":null,"abstract":"The rise of multidrug-resistant tuberculosis (TB) has increased the need for new antitubercular (anti-TB) drugs and the identification of novel drug targets. One promising target is Mycobacterium tuberculosis (Mtb) cytochrome P450 enzymes (P450s). This study focuses on the characterization of CYP135B1, a prevalent Mtb P450. Using a combination of microbiology, genomics, bioinformatics, docking, spectroscopy, and mass spectrometry, researchers successfully expressed, purified, and characterized CYP135B1. A 3D model was built with AlphaFold 3. The enzyme displayed typical features of P450 proteins and showed strong binding to imidazole derivatives. Notably, CYP135B1 metabolized the anti-TB drug SQ109 by inserting oxygen into its geranyl moiety in a manner distinct from CYP124A1. However, genetic studies using a ΔCYP135B1 mutant strain revealed that CYP135B1 is not required for SQ109’s antibacterial activity, as its deletion did not affect drug efficacy despite CYP135B1 metabolizes SQ109.","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":"11 4","pages":"869–881 869–881"},"PeriodicalIF":4.0000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterization of the Orphan Cytochrome P450 CYP135B1 from Mycobacterium tuberculosis: Involvement in Metabolism but Not in the Antibacterial Activity of the Antitubercular Drug SQ109\",\"authors\":\"Elodie Sadowski, Nicolas Pietrancosta, Romain Veyron-Churlet, Jean-Luc Boucher, Cédric Pionneau, Gilles Clodic, Lucrèce Matheron, Olivier Poch, Claudine Mayer, Emmanuelle Sachon* and Alexandra Aubry*, \",\"doi\":\"10.1021/acsinfecdis.4c0089310.1021/acsinfecdis.4c00893\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The rise of multidrug-resistant tuberculosis (TB) has increased the need for new antitubercular (anti-TB) drugs and the identification of novel drug targets. One promising target is Mycobacterium tuberculosis (Mtb) cytochrome P450 enzymes (P450s). This study focuses on the characterization of CYP135B1, a prevalent Mtb P450. Using a combination of microbiology, genomics, bioinformatics, docking, spectroscopy, and mass spectrometry, researchers successfully expressed, purified, and characterized CYP135B1. A 3D model was built with AlphaFold 3. The enzyme displayed typical features of P450 proteins and showed strong binding to imidazole derivatives. Notably, CYP135B1 metabolized the anti-TB drug SQ109 by inserting oxygen into its geranyl moiety in a manner distinct from CYP124A1. However, genetic studies using a ΔCYP135B1 mutant strain revealed that CYP135B1 is not required for SQ109’s antibacterial activity, as its deletion did not affect drug efficacy despite CYP135B1 metabolizes SQ109.\",\"PeriodicalId\":17,\"journal\":{\"name\":\"ACS Infectious Diseases\",\"volume\":\"11 4\",\"pages\":\"869–881 869–881\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00893\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsinfecdis.4c00893","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

耐多药结核病（TB）的增加增加了对新的抗结核药物（anti-TB）和确定新的药物靶点的需求。一个有希望的靶标是结核分枝杆菌（Mtb）细胞色素P450酶（P450）。本研究的重点是CYP135B1的表征，这是一种常见的Mtb P450。结合微生物学、基因组学、生物信息学、对接、光谱学和质谱，研究人员成功表达、纯化和表征了CYP135B1。利用AlphaFold 3建立三维模型。该酶表现出P450蛋白的典型特征，并与咪唑衍生物有较强的结合。值得注意的是，CYP135B1通过将氧插入其香叶基片段来代谢抗结核药物SQ109，其方式与CYP124A1不同。然而，利用ΔCYP135B1突变株进行的遗传学研究表明，CYP135B1不是SQ109抗菌活性所必需的，尽管CYP135B1代谢了SQ109，但它的缺失并不影响药效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Characterization of the Orphan Cytochrome P450 CYP135B1 from Mycobacterium tuberculosis: Involvement in Metabolism but Not in the Antibacterial Activity of the Antitubercular Drug SQ109

查看原文本刊更多论文

Characterization of the Orphan Cytochrome P450 CYP135B1 from Mycobacterium tuberculosis: Involvement in Metabolism but Not in the Antibacterial Activity of the Antitubercular Drug SQ109

The rise of multidrug-resistant tuberculosis (TB) has increased the need for new antitubercular (anti-TB) drugs and the identification of novel drug targets. One promising target is Mycobacterium tuberculosis (Mtb) cytochrome P450 enzymes (P450s). This study focuses on the characterization of CYP135B1, a prevalent Mtb P450. Using a combination of microbiology, genomics, bioinformatics, docking, spectroscopy, and mass spectrometry, researchers successfully expressed, purified, and characterized CYP135B1. A 3D model was built with AlphaFold 3. The enzyme displayed typical features of P450 proteins and showed strong binding to imidazole derivatives. Notably, CYP135B1 metabolized the anti-TB drug SQ109 by inserting oxygen into its geranyl moiety in a manner distinct from CYP124A1. However, genetic studies using a ΔCYP135B1 mutant strain revealed that CYP135B1 is not required for SQ109’s antibacterial activity, as its deletion did not affect drug efficacy despite CYP135B1 metabolizes SQ109.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES

CiteScore

9.70

自引率

3.80%

发文量

213

期刊介绍： ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.